Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval Invivyd NASDAQ:...

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration.